scholarly journals Clinical Benefit of Chemotherapy for Small-Cell Lung Cancer Patients with Extremely Poor Performance Status (PS)

2018 ◽  
Vol 26 (1) ◽  
pp. 1-6
Author(s):  
Ou Yamaguchi ◽  
Hiroshi Kagamu ◽  
Atsuto Mouri ◽  
Ayako Shiono ◽  
Harue Utsugi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Benefit ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

2020 ◽  
Vol 130 ◽  
pp. 155-167 ◽  
Author(s):  
Francesco Facchinetti ◽  
Giulia Mazzaschi ◽  
Fausto Barbieri ◽  
Francesco Passiglia ◽  
Francesca Mazzoni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients

Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?

2012 ◽  
Vol 20 (11) ◽  
pp. 2721-2727 ◽  
Author(s):  
Clarissa Seródio Baldotto ◽  
Eduardo Henrique Cronemberger ◽  
Paulo de Biasi ◽  
Mauro Zamboni ◽  
Aureliano Sousa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Palliative Care ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1995
Author(s):  
Nagio Takigawa ◽  
Nobuaki Ochi ◽  
Nozomu Nakagawa ◽  
Yasunari Nagasaki ◽  
Masataka Taoka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Lung cancer patients ≥75 years represent nearly 40% of all lung cancer patients and continue to increase. If elderly patients have a good performance status and adequate organ function, they can be treated the same as non-elderly patients. However, few comparative studies limited to elderly patients (≥75 years) have been conducted. We review the evidence on using immune check inhibitors for the treatment of elderly patients (≥75 years old) with advanced non-small cell lung cancer. Prospective randomized or non-randomized, retrospective, registrational, insurance-based, and community-based studies have shown that elderly (≥75 years) and non-elderly patients are similarly treated with immune check inhibitors effectively and safely. However, such analyses have not shown that immune check inhibitors are significantly more effective than chemotherapy alone. In addition, patient selection might be critically performed to administer immune check inhibitors in the elderly because they are more likely to have a poor performance status with comorbidities, which lead to little benefit, even in non-elderly patients. There is a need for more evidence showing the benefit of immune check inhibitors in non-small cell lung cancer patients ≥75 years.

Sign in / Sign up

Export Citation Format

Share Document